The value of digital rectal examination as a predictor of prostate cancer diagnosis among United States Veterans referred for prostate biopsy

Cancer Detection and Prevention

Volumn 30, Issue 3, 2006, Pages 269-275

  Issa, Muta M ^a,b   Zasada, Witold ^c   Ward, Kevin ^d   Hall, John A ^b   Petros, John A ^a,b   Ritenour, Chad W M ^a,b   Goodman, Michael ^d   Kleinbaum, David ^d   Mandel, Jack ^d   Marshall, Fray F ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^d EMORY UNIVERSITY   (United States)

Author keywords

Body mass index; Diagnosis; Digital rectal examination; Family history; International Prostate Symptom Score; IPSS; Normal PSA; Predictive value; Prostate cancer; Prostate Specific antigen; Sensitivity; Serum PSA; Specificity

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CONFIDENCE INTERVAL; DEMOGRAPHY; DIAGNOSTIC VALUE; DIGITAL RECTAL EXAMINATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PATIENT REFERRAL; PHYSICAL EXAMINATION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; UNITED STATES; VETERAN;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; DIGITAL RECTAL EXAMINATION; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; UNITED STATES; VETERANS;

EID: 33746774190     PISSN: 0361090X     EISSN: 15251500     Source Type: Journal    
DOI: 10.1016/j.cdp.2006.04.007     Document Type: Article

References (24)

1. Grönberg H. Prostate cancer epidemiology. Lancet 361 9360 (2003) 859-864
2. Jemal A., Murray T., Ward E., Samuels A., Tiwari R., Ghafoor A., et al. Cancer statistics, 2005. CA Cancer J Clin 55 1 (2005) 10-30
3. Weir H., Thun M., Hankey B., Ries L., Howe H., Wingo P., et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 95 17 (2003) 1276-1299
4. Harris R., and Lohr K. Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 137 11 (2002) 917-929
5. Smith R., Cokkinides V., and Eyre H. American Cancer Society guidelines for the early detection of cancer, 2003. CA Cancer J Clin 53 1 (2003) 27-43
6. Wahid Z. Task force finds evidence lacking on whether routine screening for prostate cancer improves health outcomes. J Natl Med Assoc 95 4 (2003) A20
7. Partin A., Kattan M., Subong E., Walsh P., Wojno K., Oesterling J., et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 277 18 (1997) 1445-1451
8. Matlaga B., Eskew L., and McCullough D. Prostate biopsy: indications and technique. J Urol 169 1 (2003) 12-19
9. Hoogendam A., Buntinx F., and de Vet H. The diagnostic value of digital rectal examination in primary care screening for prostate cancer: a meta-analysis. Fam Pract 16 6 (1999) 621-626
10. Department of Veterans Affairs. Facts about the Department of Veterans Affairs Washington, DC: 2006. http://www1.va.gov/opa/fact/.
11. Boyko E., Koepsell T., Gaziano J., Horner R., and Feussner J. US Department of Veterans Affairs medical care system as a resource to epidemiologists. Am J Epidemiol 151 3 (2000) 307-314
12. Cooperberg M., Lubeck D., Penson D., Mehta S., Carroll P., and Kane C. Sociodemographic and clinical risk characteristics of patients with prostate cancer within the Veterans Affairs health care system: data from CaPSURE. J Urol 170 3 (2003) 905-908
13. Kim Y., Goodman C., Omessi E., Rivera V., Kattan M., and Boone T. The correlation of urodynamic findings with cranial magnetic resonance imaging findings in multiple sclerosis. J Urol 159 3 (1998) 972-976
14. Terris M., and Stamey T. Determination of prostate volume by transrectal ultrasound. J Urol 145 5 (1991) 984-987
15. Naughton C., Smith D., Humphrey P., Catalona W., and Keetch D. Clinical and pathologic tumor characteristics of prostate cancer as a function of the number of biopsy cores: a retrospective study. Urology 52 5 (1998) 808-813
16. Okihara K., Fritsche H., Ayala A., Johnston D., Allard W., and Babaian R. Can complexed prostate specific antigen and prostatic volume enhance prostate cancer detection in men with total prostate specific antigen between 2.5 and 4.0 ng/ml. J Urol 165 6 Pt 1 (2001) 1930-1936
17. Oesterling J., Jacobsen S., Chute C., Guess H., Girman C., Panser L., et al. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 270 7 (1993) 860-864
18. Kleinbaum D., and Klein M. Logistic regression: a self-learning text (2002), Springer-Verlag, New York, NY
19. Last J. A dictionary of epidemiology (2001), Oxford University Press, Oxford
20. Basler J., and Thompson I. Lest we abandon digital rectal examination as a screening test for prostate cancer. J Natl Cancer Inst 90 23 (1998) 1761-1763
21. Carvalhal G., Smith D., Mager D., Ramos C., and Catalona W. Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng/ml or less. J Urol 161 3 (1999) 835-839
22. Schroder F., van der Maas P., Beemsterboer P., Kruger A., Hoedemaeker R., Rietbergen J., et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 90 23 (1998) 1817-1823
23. Chodak G., Keller P., and Schoenberg H. Assessment of screening for prostate cancer using the digital rectal examination. J Urol 141 5 (1989) 1136-1138
24. Freedland S., Terris M., Platz E., and Presti J.J. Body mass index as a predictor of prostate cancer: development versus detection on biopsy. Urology 66 1 (2005) 108-113